JP2024534575A5 - - Google Patents
Info
- Publication number
- JP2024534575A5 JP2024534575A5 JP2024518410A JP2024518410A JP2024534575A5 JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5 JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- uridine
- mol
- mrna
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025171713A JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247236P | 2021-09-22 | 2021-09-22 | |
| US63/247,236 | 2021-09-22 | ||
| US202163255333P | 2021-10-13 | 2021-10-13 | |
| US63/255,333 | 2021-10-13 | ||
| US202263389679P | 2022-07-15 | 2022-07-15 | |
| US63/389,679 | 2022-07-15 | ||
| PCT/US2022/044453 WO2023049299A2 (en) | 2021-09-22 | 2022-09-22 | Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Division JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534575A JP2024534575A (ja) | 2024-09-20 |
| JP2024534575A5 true JP2024534575A5 (cg-RX-API-DMAC7.html) | 2025-10-21 |
Family
ID=85721146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518410A Pending JP2024534575A (ja) | 2021-09-22 | 2022-09-22 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390520A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4405470A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024534575A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250160515A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022349449A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232742A1 (cg-RX-API-DMAC7.html) |
| GB (4) | GB2702733A (cg-RX-API-DMAC7.html) |
| IL (1) | IL311607A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003570A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049299A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018519811A (ja) * | 2015-06-29 | 2018-07-26 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用 |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク． | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| WO2025137465A1 (en) * | 2023-12-21 | 2025-06-26 | Beam Therapeutics Inc. | Base editors with modified editing windows |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
| WO2026143185A1 (en) | 2024-12-23 | 2026-07-02 | Ensoma Aps | Engineered rna-guided dna-binding polypeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| AU2016211517B2 (en) * | 2015-01-28 | 2021-05-13 | Caribou Biosciences, Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
| US11279928B2 (en) * | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| WO2017070632A2 (en) * | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| AU2018224387B2 (en) * | 2017-02-22 | 2024-08-08 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| JP7832761B2 (ja) * | 2018-06-08 | 2026-03-18 | インテリア セラピューティクス，インコーポレイテッド | 遺伝子編集のための修飾されたガイドｒｎａ |
| BR102019009665A2 (pt) * | 2018-12-21 | 2022-02-08 | Jacques P. Tremblay | Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9 |
| CA3174708A1 (en) * | 2020-03-04 | 2021-09-10 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
| US12115230B2 (en) * | 2020-04-09 | 2024-10-15 | Verve Therapeutics, Inc. | Base editing of ANGPTL3 and methods of using same for treatment of disease |
-
2022
- 2022-09-22 GB GB2606215.8A patent/GB2702733A/en active Pending
- 2022-09-22 IL IL311607A patent/IL311607A/en unknown
- 2022-09-22 GB GB2509407.9A patent/GB2700667A/en active Pending
- 2022-09-22 JP JP2024518410A patent/JP2024534575A/ja active Pending
- 2022-09-22 EP EP22873600.5A patent/EP4405470A4/en active Pending
- 2022-09-22 GB GB2509406.1A patent/GB2701689A/en active Pending
- 2022-09-22 KR KR1020257035760A patent/KR20250160515A/ko active Pending
- 2022-09-22 AU AU2022349449A patent/AU2022349449A1/en active Pending
- 2022-09-22 CA CA3232742A patent/CA3232742A1/en active Pending
- 2022-09-22 KR KR1020247013385A patent/KR20240099200A/ko active Pending
- 2022-09-22 GB GB2405381.1A patent/GB2628238A/en active Pending
- 2022-09-22 WO PCT/US2022/044453 patent/WO2023049299A2/en not_active Ceased
- 2022-09-22 MX MX2024003570A patent/MX2024003570A/es unknown
-
2024
- 2024-03-21 US US18/611,988 patent/US20240390520A1/en active Pending
-
2025
- 2025-10-10 JP JP2025171713A patent/JP2026012737A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7506670B2 (ja) | 脂質ナノ粒子製剤 | |
| US12251470B2 (en) | Lipid nanoparticle formulations | |
| Melamed et al. | Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery | |
| EP4479535A1 (en) | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia | |
| JP2025019119A (ja) | ケイ素を含有するカチオン性脂質 | |
| JP2022530018A (ja) | 脂質ナノ粒子 | |
| JP2023507521A (ja) | シュタルガルト病の処置におけるヌクレオチド脱アミノ化のためのアンチセンスオリゴヌクレオチド | |
| JP2022523302A (ja) | アッシャー症候群の処置のためのｒｎａ編集オリゴヌクレオチド | |
| JP2021526804A5 (cg-RX-API-DMAC7.html) | ||
| CN117479963A (zh) | Peg脂质和脂质纳米粒子 | |
| JP2021519071A (ja) | シュードウリジン化のための核酸分子 | |
| KR20220140531A (ko) | 간 성상 세포에 대한 치료제의 지질 나노입자 전달을 위한 양이온성 지질 | |
| JP2025527583A (ja) | 脂質ナノ粒子の組成物 | |
| KR20230014695A (ko) | 이작용성 분자 및 이의 사용 방법 | |
| JP2024543000A (ja) | 操作されたｒｎａ | |
| CA3173528A1 (en) | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression | |
| EP3420093A1 (en) | Micelle based system nuclease encapsulation for in-vivo gene editing | |
| CN121152628A (zh) | 治疗性寡核苷酸的局部递送 | |
| US20220288237A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| AU2024365431C1 (en) | Efficient, low off-target gene editing tool | |
| AU2023265171B2 (en) | Oligonucleotide | |
| EP4716741A2 (en) | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression | |
| WO2025165840A1 (en) | Compositions and methods of treating cardiovascular disease | |
| CN118613582A (zh) | 工程化rna |